文献速递神经肿瘤

自噬调节胶质母细胞瘤细胞对Selinexor介导的XPO1抑制的敏感性

Autophagy modulates glioblastoma cell sensitivity to Selinexor-mediated XPO1 inhibition.
PubMed 文献 · Neuro Oncol · 2025-01-01

本研究以患者来源的胶质母细胞瘤(GBM)细胞为对象,发现Selinexor抑制XPO1后主要诱导自噬而非凋亡,自噬对细胞起保护作用;遗传或药理抑制自噬可增敏Selinexor并伴凋亡诱导,颅内PDX中Selinexor联合氯喹较单药显著抑制肿瘤生长并延长小鼠生存。

要点

  • Selinexor在GBM细胞中主要诱导自噬而非凋亡,自噬为XPO1抑制的在靶后果。
  • 遗传或药理抑制自噬可增敏Selinexor毒性,并伴随凋亡诱导。
  • 颅内PDX中Selinexor联合氯喹较单药显著抑制肿瘤生长并延长小鼠生存。

核心结论

  • 结果提示自噬激活为GBM细胞对抗Selinexor的保护机制。
  • Selinexor联合自噬抑制剂可能成为增强Selinexor诱导细胞死亡的可行的方式。

研究设计与样本

  • 患者来源GBM细胞经Selinexor处理,监测药物反应与自噬水平。
  • 以CRISPR/Cas9编辑生成纯合C528S XPO1突变GBM43细胞。
  • 评估单用Selinexor或联合自噬抑制剂治疗。
  • 分析bulk组织、单细胞和空间转录组,并进行分子对接。
  • 开展颅内PDX研究。

主要发现

  • 所有细胞系均呈剂量和时间依赖性细胞活力下降,但最显著的分子反应是诱导自噬而非凋亡。
  • Selinexor诱导的自噬为XPO1抑制的在靶后果,可被表达突变、抗Selinexor的XPO1形式所减轻。
  • Selinexor诱导的自噬至少部分与转录因子TFEB的核滞留相关。
  • 遗传或药理抑制自噬使细胞对Selinexor毒性增敏,并伴凋亡诱导。
  • 颅内PDX中Selinexor联合自噬抑制剂氯喹较单药显著阻碍肿瘤生长并延长小鼠生存。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Selinexor is a selective inhibitor of exportin-1 (XPO1), a key mediator of the nucleocytoplasmic transport for molecules critical to tumor cell survival. Selinexor's lethality is generally associated with the induction of apoptosis, and in some cases, with autophagy-induced apoptosis. We performed this study to determine Selinexor's action in glioblastoma (GBM) cells, which are notoriously resistant to apoptosis. METHODS: Patient-derived GBM cells were treated with Selinexor, and drug response and autophagy levels were monitored. Homozygous C528S XPO1 mutant GBM43 cells were generated by CRISPR/Cas9 editing. Single Selinexor or combination treatment with autophagy inhibitors was evaluated. In addition, bulk-tissue, single-cell, and spatial transcriptome were analyzed, and molecular docking was performed. RESULTS: Although all cell lines exhibited a dose- and time-dependent reduction of cell viability, the most profound molecular response to Selinexor was induction of autophagy instead of apoptosis. Selinexor-induced autophagy was an on-target consequence of XPO1 inhibition, and could be mitigated by expression of a mutant, Selinexor-resistant form of XPO1, and Selinexor-induced autophagy was related at least in part to nuclear trapping of the transcription factor TFEB. Furthermore, genetic or pharmacologic suppression of autophagy sensitized the cells to Selinexor-induced toxicity in association with the induction of apoptosis. Finally, in intracranial PDX studies, the combination of Selinexor with the autophagy inhibitor chloroquine significantly impeded tumor growth and extended mouse survival relative to single-agent treatment. CONCLUSION: These results suggest that activation of autophagy confers a protective mechanism against Selinexor in GBM cells, and that the combination of Selinexor with autophagy inhibitors may serve as a viable means to enhance Selinexor-induced cell death.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Tang Y, Sprinzen L, Terada Y, et al. Autophagy modulates glioblastoma cell sensitivity to Selinexor-mediated XPO1 inhibition. Neuro Oncol. 2025. PMID: 39731209. doi:10.1093/neuonc/noae280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。